China's Sinovac Biotech is expected to expand its annual production capacity of CoronaVac to 2 billion doses, as a third production line was completed and put into production on Thursday, announced the company on Friday. 

More than 200 million doses of CoronaVac, an inactivated COVID-19 vaccine developed by Sinovac, including the semi-finished ones, have been delivered to in China and 26 other countries and regions. Over 100 million doses have been administered around the globe. So far, the Sinovac vaccine has received emergency use approval or conditional marketing authorization from more than 30 countries, according to the company.